## ICMJE DISCLOSURE FORM

Date: Nov 10<sup>th</sup>, 2023 Your Name: Fu-Zhao Ma

Manuscript: T2 relaxation time elongation of hepatocellular carcinoma relative to native liver tissue leads to an underestimation of perfusion fraction measured by standard intravoxel incoherent motion

MR imaging

Manuscript number: QIMS-23-1437

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Ti	Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone				
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None				
3	Royalties or licenses	X_None				

4	Consulting fees	X_None			
5	Payment or honoraria for	X_None			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	X None			
	testimony				
	-				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued	XNone			
	or pending				
9	Participation on a Data	X_None			
	Safety Monitoring Board				
	or Advisory Board				
10	Leadership or fiduciary	XNone			
	role in other board, society, committee or				
	advocacy group, paid or				
	unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	X_None			
	financial interests				
Please summarize the above conflict of interest in the following box:					
XNone					

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: Nov 10<sup>th</sup>, 2023

Your Name: Yi-Xiang Wang

Manuscript: T2 relaxation time elongation of hepatocellular carcinoma relative to native liver tissue leads to an underestimation of perfusion fraction measured by standard intravoxel incoherent motion

MR imaging

Manuscript number: QIMS-23-1437

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Ti	Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone				
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None				
3	Royalties or licenses	X_None				

4	Consulting fees	X_None			
5	Payment or honoraria for	X_None			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	X None			
	testimony				
	-				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued	XNone			
	or pending				
9	Participation on a Data	X_None			
	Safety Monitoring Board				
	or Advisory Board				
10	Leadership or fiduciary	XNone			
	role in other board, society, committee or				
	advocacy group, paid or				
	unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	X_None			
	financial interests				
Please summarize the above conflict of interest in the following box:					
XNone					

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.